Overview

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether oral administration of MK-4827 to participants with advanced solid tumors is generally safe and well tolerated.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Niraparib